Tafamidis

Nat Rev Drug Discov. 2012 Mar 1;11(3):185-6. doi: 10.1038/nrd3675.

Abstract

In November 2011, tafamidis (Vyndaqel; Pfizer), a small molecule that inhibits the dissociation of transthyretin tetramers, was granted marketing authorization by the European Commission for the treatment of transthyretin amyloidosis in adult patients with stage 1 symptomatic polyneuropathy to delay peripheral neurological impairment.

Publication types

  • News

MeSH terms

  • Amyloid Neuropathies / drug therapy*
  • Amyloid Neuropathies / metabolism
  • Animals
  • Benzoxazoles / chemistry
  • Benzoxazoles / metabolism
  • Benzoxazoles / therapeutic use*
  • Clinical Trials as Topic / trends
  • Humans
  • Prealbumin / antagonists & inhibitors*
  • Prealbumin / metabolism

Substances

  • Benzoxazoles
  • Prealbumin
  • tafamidis